PT  - JOURNAL ARTICLE
AU  - Gibney, Geoffrey T.
AU  - Smalley, Keiran S.M.
TI  - An Unholy Alliance: Cooperation between BRAF and NF1 in Melanoma Development and BRAF Inhibitor Resistance
AID  - 10.1158/2159-8290.CD-13-0017
DP  - 2013 Mar 01
TA  - Cancer Discovery
PG  - 260--263
VI  - 3
IP  - 3
4099  - http://cancerdiscovery.aacrjournals.org/content/3/3/260.short
4100  - http://cancerdiscovery.aacrjournals.org/content/3/3/260.full
SO  - CANCER DISCOVERY2013 Mar 01; 3
AB  - Summary: In this issue of Cancer Discovery, 2 studies provide new evidence implicating loss of the tumor suppressor neurofibromin (NF1) in the biologic behavior of cutaneous melanoma. The first study from Maertens and colleagues describes a new transgenic mouse model in which mutant BRAF cooperates with NF1 loss to drive melanoma development through the abrogation of oncogene-induced senescence. The second, from Whittaker and colleagues, used a high-throughput short hairpin RNA screening approach to identify NF1 loss as a key mediator of acquired and intrinsic BRAF inhibitor resistance. Together these studies provide new insights into the signaling that underlies melanoma initiation and progression and suggests novel therapeutic strategies for patients whose melanomas are BRAF-mutant/NF1-deficient. Cancer Discov; 3(3); 260–3. ©2013 AACR. See related article by Maertens et al., p. 338 See related article by Whittaker et al., p. 350